Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May 14;4(5):e004664.
doi: 10.1136/bmjopen-2013-004664.

Safety of 8-aminoquinolines given to people with G6PD deficiency: protocol for systematic review of prospective studies

Olalekan A Uthman  1 , Rachel Saunders  2 , David Sinclair  2 , Patricia Graves  3 , Hellen Gelband  4 , Aileen Clarke  5 , Paul Garner  2
Affiliations

Safety of 8-aminoquinolines given to people with G6PD deficiency: protocol for systematic review of prospective studies

Olalekan A Uthman et al. BMJ Open. .

Abstract

Introduction: A single dose or short course of primaquine given to people infected with malaria may reduce transmission of Plasmodium falciparum through its effects on gametocytes. Primaquine is also known to cause haemolysis in people with variants of glucose-6-phosphate dehydrogenase (G6PD) deficiency. The objective of this systematic review was to assess the risk of adverse effects in people with G6PD deficiency given primaquine or other 8-aminoquinoline (8AQ) as a single dose or short course (less than 7 days).

Methods and analysis: We will search the following databases: Cochrane Infectious Diseases Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and LILACS. Prospective cohort studies, randomised and quasi-randomised trials that evaluated 8AQs for whatever reason in adults or children with a known G6PD deficiency will be included. Two authors will independently assess each study for eligibility, risk of bias and extract data.

Ethics and dissemination: This systematic review will be published in a peer-reviewed journal. Brief reports of the review findings will be disseminated directly to the appropriate audiences and the WHO Technical Expert Group in Malaria Chemotherapy. As no primary data collection will be undertaken, no additional formal ethical assessment and informed consent are required.

Protocol registration in prospero: The protocol is registered with PROSPERO, registration number CRD42013006518.

Keywords: Infectious Diseases; Preventive Medicine; Public Health.

PubMed Disclaimer

References

    1. WHO. Guidelines for the treatment of malaria. 2nd edn Geneva, Switzerland: World Health Organization, 2010
    1. Betuela I, Bassat Q, Kiniboro B, et al. Tolerability and safety of primaquine in Papua New Guinean children 1 to 10 years of age. Antimicrob Agents Chemother 2012;56:2146–9 - PMC - PubMed
    1. Vale N, Moreira R, Gomes P. Primaquine revisited six decades after its discovery. Eur J Med Chem 2009;44:937–53 - PubMed
    1. Bunnag D, Karbwang J, Thanavibul A, et al. High dose of primaquine in primaquine resistant vivax malaria. Trans R Soc Trop Med Hyg 1994;88:218–19 - PubMed
    1. Baird JK, Lacy MD, Basri H, et al. Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis 2001;33:1990–7 - PubMed

Publication types

MeSH terms